Turtle Creek Wealth Advisors LLC Buys Shares of 121 Humana Inc. (NYSE:HUM)

Turtle Creek Wealth Advisors LLC bought a new stake in Humana Inc. (NYSE:HUM) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 121 shares of the insurance provider’s stock, valued at approximately $55,000.

Several other hedge funds have also recently bought and sold shares of HUM. Cibc World Market Inc. boosted its stake in shares of Humana by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock valued at $2,484,000 after purchasing an additional 217 shares in the last quarter. Blair William & Co. IL boosted its stake in shares of Humana by 0.6% in the 1st quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock valued at $2,463,000 after purchasing an additional 32 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of Humana by 0.5% in the 1st quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock valued at $2,135,000 after purchasing an additional 26 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Humana by 19.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock valued at $268,000 after purchasing an additional 98 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of Humana by 25.0% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock valued at $12,971,000 after purchasing an additional 5,964 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Analysts Set New Price Targets

HUM has been the topic of several recent research reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $391.00 target price on shares of Humana in a research report on Wednesday. Mizuho cut their target price on shares of Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, January 26th. Raymond James initiated coverage on shares of Humana in a research report on Friday, March 22nd. They set a “market perform” rating on the stock. Bank of America reiterated a “neutral” rating and set a $342.00 target price (down from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Finally, The Goldman Sachs Group cut their target price on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus price target of $465.42.

Insider Buying and Selling at Humana

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.32% of the company’s stock.

Humana Price Performance

Shares of NYSE:HUM opened at $316.29 on Friday. The company’s 50-day moving average is $348.54 and its 200 day moving average is $431.10. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. The company has a market capitalization of $38.16 billion, a P/E ratio of 15.96, a price-to-earnings-growth ratio of 1.87 and a beta of 0.45. Humana Inc. has a fifty-two week low of $299.23 and a fifty-two week high of $541.21.

Humana (NYSE:HUM) last released its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). The business had revenue of $26.46 billion for the quarter, compared to analysts’ expectations of $25.47 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. Humana’s revenue for the quarter was up 17.9% compared to the same quarter last year. During the same period last year, the company earned $1.62 earnings per share. On average, equities research analysts forecast that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.12%. The ex-dividend date of this dividend is Wednesday, March 27th. Humana’s dividend payout ratio (DPR) is presently 17.86%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.